DDI-DrugBank.d609.s0 >> An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. >> 32-42,69-81,117-124,151-163
DDI-DrugBank.d609.s1 >> Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response. >> 95-107
